**Review Article**

**A Review of Complementary and Alternative Medicine Therapies on Muscular Atrophy: A Literature Review of In Vivo/In Vitro Studies**

Seong-Mok Jeong, Byung-Kwan Seo, Yeon-Cheol Park, and Yong-Hyeon Baek

Department of Acupuncture & Moxibustion, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea

Correspondence should be addressed to Yong-Hyeon Baek; byhacu@khu.ac.kr

Seong-Mok Jeong and Byung-Kwan Seo contributed equally to this work.

Received 13 July 2018; Revised 28 August 2018; Accepted 22 October 2018; Published 18 November 2018

Academic Editor: Mariangela Rondanelli

Copyright © 2018 Seong-Mok Jeong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Objective.** The objective of this review is to evaluate the recent treatment and study trends of complementary and alternative medicine (CAM) treatments on muscular atrophy by reviewing in vivo/in vitro studies. **Materials and Methods.** The searches were conducted via electronic databases including PubMed, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang MED, and five Korean databases. Only in vivo and in vitro studies were included in this study. **Results.** A total of 44 studies (27 in vivo studies, 8 in vitro studies, and 9 in vivo with in vitro) were included. No serious maternal or fetal complications occurred. There were various animal models induced with muscular atrophy through “hindlimb suspension”, “nerve damage”, “alcohol or dexamethasone treatment”, “diabetes”, “CKD”, “stroke”, “cancer”, “genetic modification”, etc. In 28 of 36 articles measuring muscle mass, CAM significantly increased the mass. Additionally, 10 of them showed significant improvement in muscle function. In most in vitro studies, significant increases in both the diameter of myotubes and muscle cell numbers were reported. The mechanisms of action of protein synthesis, degradation, autophagy, and apoptotic markers were also investigated. **Conclusions.** These results demonstrate that CAM could prevent muscular atrophy. Further studies about CAM on muscular atrophy are needed.

1. **Introduction**

Muscle atrophy is defined as a reduction in muscle mass, which is a concept that covers partial or complete wasting away from muscle. In general, functional and morphological changes caused by muscular atrophy usually result in decreased muscle fiber cross-sectional area, protein content, muscle strength, and increased insulin resistance [1]. Muscle atrophy occurs in cachexia, a comorbidity of abnormal conditions such as cancer, AIDS, congestive heart failure, and chronic obstructive pulmonary disease (COPD). It also occurs in sarcopenia, a decrease in muscle mass and strength associated with aging [2].

Although the causes of muscle atrophy are not fully understood, numerous factors contributing to the deterioration of muscle atrophy have been found through recent studies. Among these, decreased alpha motor neuron numbers, increased inflammatory cytokinesis, and decreased hormonal function are considered important factors in its pathogenesis [3].

Meanwhile, according to research by Alfonso et al. [4], the prevalence of sarcopenia in senior citizens aged 60 to 70 years was found to be 5-13% and 50% in patients over 80 years. Around the world, the population over 60 years was estimated to be about 60 million in the year 2000 and has been projected to be about 1.2 billion by 2025 and 2 billion by 2050. On condition that the current average prevalence of muscle loss is maintained, at least 50 million people to date and about 200 million people in the next 40 years will be affected by sarcopenia.

In complementary and alternative medicine, symptoms of muscular atrophy are treated using acupuncture, chuna...
treatment, and herbal medicine. In addition to these clinical treatments, many studies on complementary and alternative medicine (CAM) therapies for muscular atrophy have been conducted recently, but the results in literature have been insufficient. Against this background, we performed a literature review of CAM on muscular atrophy to establish a research model and suggest a direction for future research.

2. Method

2.1. Search Strategies. We conducted this literature review of in vivo/in vitro studies through Korean and foreign electronic database searches. Foreign databases used included PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang MED. Domestic databases searched included Korean Traditional Knowledge Portal (KTKP), Oriental Medicine Advanced Searching Integrated System (OASIS), Research Information Services (RISS), National Assembly Library, and the Korean studies information Service System (KISS). In the Korean databases, “muscular atrophy”, “muscle loss”, and “complementary and alternative medicine” were used as search terms. In CNKI and Wanfang MED, we used cross-language searches and related search terms which were “muscle atrophy”, “muscle loss”, and “肌肉減少”.

The search strategy used in the searches in PubMed and the Cochrane Library was based on a combination of medical subject headings outlined in Table 1. The searches were conducted independently by two investigators (SM Jeong, YC Park) who retrieved relevant studies published before August 2018. After retrieving the articles, we extracted and classified the data by animal or cell models, intervention type (herbal medicine, acupuncture, and moxibustion), and outcome measures (muscle mass, strength, and histological and/or biochemical measurements). The extracted data was then verified by the third author (YH Baek). Disagreements were resolved by consensus through face-to-face discussions among the three authors.

2.2. Study Selection. The inclusion criteria for the literature review were as follows: (1) articles on complementary and alternative medicine treatments for muscular atrophy and (2) in vivo or in vitro studies, while the exclusion criteria included the following: (1) clinical trial; (2) articles that were not original; (3) articles that were not in English, Korean, or Chinese; (4) duplicate studies. We also excluded studies that did not focus on muscle loss or muscle cell loss and those which did not use complementary and alternative medicine treatment. Full articles meeting the inclusion criteria were retrieved and read carefully.

3. Results

3.1. Literature Search. The search initially yielded 973 articles out of which duplicates were eliminated. After screening the titles, 872 articles were excluded due to a lack of adequate coverage of the topic of interest, and after full text assessment, 57 additional articles were excluded for one or more of the following reasons: (1) articles that were not based on original research; (2) articles that did not involve in vivo or in vitro studies; and (3) abstracts and comments. Finally, 44 articles were included in our literature review (Figure 1).

3.2. In Vivo Studies. A total of 36 articles (27 of which were in vivo only and 9 of which were in vivo with in vitro studies) were classified as in vivo studies in our review.
Evidence-Based Complementary and Alternative Medicine

3.2.1. Animal Model Species. The most commonly used model was the Sprague-Dawley rat which was used by 22 out of the 36 studies. C57BL/6 mice were used in 6 studies, BALB/c mice were used in 2 studies, and DBA/1 J mice, Kunming mice, and SPF/VAF mice were used in one study each. Three papers did not mention which animal models were used.

There were variations in the ages of the animals used in the studies, with 16-, 12-, 10-, 9-, 8-, 7-, and 6-week-old animals being used in 1, 2, 11, 1, 6, 1, and 7 studies, respectively. In one study, the ages of animals used in the test group differed from that of the control group, being 5 and 19 months, respectively. With regard to the sex of the animals, male rats were predominantly used, featuring in 30 studies, while one study used only female rats and one study used a combination of male and female animals. The other studies did not mention sex of the animals.

In order to induce muscular atrophy, various disease models were used in the studies. The most commonly used model for muscular atrophy was the hindlimb suspension (HS) method, developed by Morey-Holton and Wronski [49]. HS rat model was used in 7 of the 36 studies. The next commonly used model was nerve damage-induced muscular atrophy model which was used in 6 studies. Among these studies, direct injury to the sciatic nerve or the peroneal nerve was used to cause atrophy. The chronic kidney disease (CKD) model, in which induction was done by 5/6 nephrectomy was used in 5 studies. The alcohol-induced muscular atrophy model, transgenic model, and the cancer-induced cachexia model (C26-colon-adenocarcinoma implanted) were used, and each of these models was used in three of the 36 studies reviewed. In two studies, diabetes was induced by the administration of streptozotocin to evaluate muscular dystrophy due to diabetes. There were 2 studies using stroke models (middle cerebral artery occlusion, MCAO) and one study for each of the following models: chronic obstructive pulmonary disease (COPD), collagen-induced arthritis (CIA), dexamethasone-induced atrophy, spinal cord injury, and the aging models (Figure 2).

3.2.2. Interventions. The most common types of intervention were herbal medicines which were used in 28 studies. In addition, there were 7 studies using electroacupuncture and one study using moxibustion (Figure 3). The treatment periods were 12 days in 2 studies, 2-4 weeks in 24 studies, 1-6
months in 8 studies, and 38 weeks in 1 study. One study did not limit the treatment period.

3.2.3. Outcomes. Muscle mass, the most common primary outcome, was investigated in 28 out of the 36 studies. All except one reported a significant increase in muscle mass. Ten articles investigated muscle function, all of which reported significant increases in muscle mass (Tables 2 and 3).

(A) Hindlimb Suspension Model. In the study conducted by Akiko Onda et al., electroacupuncture (E-AT) inhibited the expression of the MuRF-1 gene. E-AT also elevated the expression of Akt1 and TRPV4 [5]. In the study by Zhang ZK et al., icaritin extract was used which inhibited reduced phosphorylation of PI3K-p110, thereby promoting protein synthesis. In addition, the extract inhibited muscle atrophy through modulation of the FoxO3a and FoxO1, the O subclasses of the forkhead family of transcription factors [33]. In the study by Soh KS et al., after using KangwhalSokdan-tang (KWSDT), the ratio of type I muscle fiber/type II fiber was increased showing that KWSDT inhibited early muscular atrophy. IGF-1 and MyoD were also measured and increasing of these key myogenic factors was involved in the improvement of muscle mass [21].

In Cho SG et al., the combination of Schisandra chinensis Baill, Lycium chinense Mill, and Eucommia ulmoides Oliv inhibited muscular atrophy and increased muscle strength and cross-sectional area of muscle fiber [36]. Zhu M et al. also reported the similar effects on muscular atrophy by using Bu Zhong Yi Qi decoction [37].

Bax and Bcl-2 were measured in Kim BH’s study. Daeyeoung-jeon extract significantly reduced the immunoreactivity of Bax and increased Bcl-2 in gastrocnemius muscle [23]. In another study by Kim BH, Dangguibohyul-tang (Dangguibuxuetang) extract significantly enhanced the antioxidant enzyme, Cu/Zn-SOD which inhibited disuse muscular atrophy by suppressing oxidative damage [24].

(B) Nerve Damaged Model. In the studies using nerve damaged model, one study provided treatment with Radix Puerariae extract and the other used Radix Dipsaci extract. Both studies measured Bcl-2 and Bax. While Radix Puerariae extract was found to significantly inhibit Bax but not Bcl-2 [15], Radix Dipsaci extract significantly inhibited both Bax and Bcl-2 expression [17].

In the study by Zhou L. et al., the result indicated that Buyang Huanwu Tang (BYHWT) decreased inflammatory cells through the activation of angiopoietin-like protein 4 (ANGPTL4) and inhibited muscle cell apoptosis in the denervated-dependent skeletal muscle atrophy model. The effect of BYHWT was mediated by increased expression of NF-κB and MuRF-1 [27]. Another study by Zhou L. et al., BYHWT increased the NF-κB p65 and MuRF1, too [30].

Yu J. et al. applied E-AT on penicillin injection-induced sciatic nerve injury model and the treatment alleviated muscular atrophy by upregulating agrin and acetylcholine receptor-ε (AChR-ε), and downregulating AChR-γ associated in neuromuscular transmission [28]. In Cao R. et al., E-AT on sciatic nerve injury inhibited muscle cell apoptosis by suppressing Bax, cytochrome C, and caspase-3 [31].

(C) Stroke-Induced Model. In the studies by Lee et al. and Han et al., the Radix Dipsaci extract inhibited the “slow-to-fast shift” phenomenon in muscle fibers and MHC-II expression while increasing MyoD expression and thereby significant efficacy in muscle recovery [18, 19].

(D) Diabetes-Induced Model. Insulin-like growth factor 1 (IGF-1) was the main factor measured in both studies using diabetes-induced model. In the study by Su Z et al., low-frequency electroacupuncture stimulation (LFES) promoted IGF-1 [6]. Additionally, LFES increased Pax7 genes, MyoD, myogenin, and eMyHC. In a study by Zhang J. et al., the Zhimu-Huangbai (1:1) herb pair was used, which promoted IGF-1 and inactivated FOXO3 protein [14].

(E) Chronic Kidney Disease-Induced Model. In a study by Hu L. et al., LFES promoted the IGF-1 signaling pathway by decreasing microRNA-1 and microRNA-206 which suppressed IGF-1 transcription [10]. In Lu L. et al., astragalus polysaccharide (APS) reduced proinflammatory cytokines and regulated oxidative stress, thereby inhibiting muscle loss [35].

In Wang D. et al., the administration of Jian-Pi-Yi-Shen (JYS) decoction prevented muscle loss, muscle protein degradation, and increased muscle protein synthesis. In addition, JYS decoction not only inhibited FoxO3a activation and ubiquitin-proteasome system (UPS), but also increased Cyt IV, NRF-1, and PGC-1α [25]. Atrogin-1 and MuRF-1 were also measured in the study by Geng Z et al., and astragalus polysaccharide significantly reduced the expression of atrogin-1 and ubiquitin in rat skeletal muscle [38].

In CKD-induced mice, the levels of autophagy-related proteins including Bnip3 and Beclin-1 were increased. Likewise, the ratio of the autophagy proteins LC3II-to-LC3I, associated with autophagosome formation, was increased. Su Z. et al. suggested that using Acu/LFES suppressed the CKD-induced upregulation of autophagy by inhibiting those proteins [26].
| First Author (year) (Ref) | Design | Origin | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|--------------------------|--------|--------|-------------------------|--------------------------|----------|-----------------|-----------------------------------|---------------|
| Onda A 2011 [5]          | In vivo| Japan  | Total n = 28 control (7)<br>HS (7)<br>HS + MA (7)<br>HS + EA (7) | Hindlimb suspension (HS) rat model (C57BL/6, 8 wk, M) | 2 wk     | (1) Muscle weight/body weight<br>(2) Cross sectional area (CSA)<br>(3) Muscle-proteolytic genes<br>(4) Protein synthesis markers | MA (manual acupuncture): 30 min on the gastrocnemius, 5 mm insert<br>EA (electro-acupuncture): 30 min on the gastrocnemius, 5 mm insert, 1 Hz, 6.5 mA 1/day for 2wk | (1) Muscle/body weight: HS < HS+MA (7%, p<0.05)<br>HS < HS+EA (10%, p<0.001)<br>(2) CSA: HS > HS+EA (p<0.05)<br>(3) Atrogin-1↓, MuRF1↓ in EA (p<0.01 vs. HS)<br>Atrogin-1↓ in MA (p<0.01 vs. HS)<br>(4) Akt↑, TRPV4↑ in MA (p<0.05 vs. HS) |
| Su Z 2015 [6]            | In vivo| China  | Total n = 48 control (12)<br>LFES (12)<br>Diabetes (12)<br>Diabetes + LFES (12) | Streptozotocin-induced diabetic mouse model (C57BL/6, 8-10 wk, M) | 2 wk     | (1) Muscle grip function<br>(2) Muscle weight/body weight<br>(3) Muscle regeneration proteins<br>(4) Protein synthesis markers | LFES (Low-frequency electric stimulation): positive point at GB34, negative point at ST36 20 Hz, 1 mA for 15 min 1/day for 2wk | (1) Muscle grip function: DM + LFES > DM (p<0.05)<br>(2) Muscle weight (Soleus, Extensor digitorum longus): DM + LFES > DM (p<0.05)<br>(3) Pax7↑, Myod↑, myogenin↑, eMyHC↑ (p<0.05 vs. DM)<br>(4) IGF-1↑, p-Akt↑, mTOR↑, p70S6K↑ (p<0.05 vs. DM) |
| Dong Y 2015 [7]          | In vivo| China  | Total n =72 Control + Saline (12)<br>Control + BJ (12)<br>Control + AP (12)<br>COPD + Saline (12)<br>COPD + BJ (12)<br>COPD + AP (12) | Klebsiella pneumoniae & cigarette smoke-induced COPD rat model (Sprague-Dawley (SD) rat, 2 mo, M/F) | 12 wk    | (1) Muscular tension<br>(2) Muscular fatigue index<br>(3) Expressions of Bnip3 and Cyto-C in muscle tissues | BJ: Bufei Jianpi granules (5 g kg⁻¹ d⁻¹)<br>AP: Aminophylline (2.3 mg kg⁻¹ d⁻¹) Intragastrically inserted | (1) Muscular tension: BJ > Saline, AP (p<0.05)<br>(2) Muscular fatigue: BJ < Saline, AP (p<0.05)<br>(3) Bnip3↓, CytoC↓ (p<0.05 vs. Saline, AP) |
| First Author (year) (Ref) | Design | Origin | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|---------------------------|--------|--------|-------------------------|-------------------------|----------|-----------------|-----------------------------------|----------------|
| Zhuang P 2016 [8]         | In vivo | China  | Total n = 60 Normal + Water (C) (20) | C26-colon-adenocarcinoma-implanted mice (C57BL/6, 4-6 wk, M) | 19 d | (1) Muscle weight (2) Muscle function (3) Pro-inflammatory cytokines (4) Atrophy-related genes (5) IGF-1/Akt and autophagy pathway | ZHBP: Zhimu (Rhizoma Anemarrhena) and Huangbai (Cortex Phellodendri) 1:1 extracted with ethanol 104 mg/kg/day, oral intake | (1) Muscle weight: ZHBP > M (p<0.05) (2) Grip-strength: ZHBP > M (p<0.01) (3) TNF-α, IL-6: ZHBP < M (p<0.05) IGF-1: ZHBP > M (p<0.01) (4) Atrogin-1, MuRF1 (p<0.05 vs. M) (5) SRT110, p-Akt, FOXO3a (p<0.05 vs. M) |
| Kishida Y 2014 [9]        | In vivo | Japan  | Total n = 41 SAMP8 + N (10) | Senescence-accelerated rat model (SAMP8) Senescence-accelerated aging-resistant rat model (SAMRI) (7 wk, M) | 38 wk | (1) Muscle fiber size (2) Myofiber balance (fast/slow) (3) Glycogen synthesis proteins (4) Muscle atrophy proteins | GJG: Go-sha-jinki-Gan 4% (w/w) GJG daily for 38 wk N (Control): normal diet | (1) Muscle fiber: P8+N < P8+GJG (p<0.0001) (2) Fast skeletal muscle: P8+N < P8+GJG (p<0.0001) p-AMPK↑, PGC-1α↑ in P8+GJG (3) IGF-1↑, p-Akt↑, p-GSK3β↑ (4) p-FoxO4↑, MuRF1↑, TNF-α↑ |
| Hu L 2015 [10]           | In vivo | China  | Total n = 48 Sham (Sham op) (12) Sham-LFES (12) CKD (12) CKD-LFES (12) | 5/6-nephrectomized rat model (mice with chronic kidney disease) (n r, n r, n r) | 15 d | (1) Muscle mass (soleus & extensor digitorum longus) (2) Grip strength meter (3) Synthesis-related proteins (4) IGF-1 and MGF | LFES: Low-frequency electric Stimulation acupuncture positive point (GB34) negative point (ST36), 20Hz, lmA 15 min 1/day for 15 d * needles: 0.25 mm (diameter) | (1) Muscle mass: Sham ≥ Sham-LFES CKD < CKD-LFES (p<0.05) (2) Muscle function: CKD < CKD-LFES (p<0.05) (3) p-Akt, mTOR, p70S6K: CKD < CKD-LFES (p<0.05) (4) IGF-1, MGF: CKD < CKD-LFES (p<0.05) |
| First Author (year) (Ref) | Design | Origin | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|---------------------------|--------|--------|-------------------------|--------------------------|----------|------------------|-----------------------------------|---------------|
| Nakashima Y 2014 [11]    | In vivo | Japan  | Total n = 16 Control (8) CSD (8) | ALDH2 * 2 Tg rat model (selectively decrease ALDH2 activity) (C57BL/6 mice, n r, M) | 6 mo     | (1) Oxidative stress marker (2) Muscle tissue injury marker (3) Body weight (4) Gastrocnemius cell size (5) Mitochondrial cytochrome C oxidase activity | CSD: Chlorella-supplemented diet 1% for 6 mo Control: fed basic diet | (1) Urinary isoprostane: CSD < Control (after 4 mo, p<0.05) MDA, HAE: CSD < Control (p<0.01) (2) CPK activity: CSD < Control (p<0.05) CKMB activity: CSD < Control (3) Body weight: CSD > Control (after 4 mo, p<0.05) (4) Cell size: CSD > Control (p<0.05) (5) Cyto-C oxidase activity: CSD < Control (p<0.01) |
| Kim MJ 2012 [12]         | In vivo | Korea  | Total n = 12 Control (4) CIA (4) CIA+Moxi (4) | Collagen-induced arthritis (CIA) rat model (Inj of bovine type II collagen) (DBA/1J mice, 6 wk, M) | 3 wk     | (1) Cross-sectional area (2) Phospho-ERK1/2 (3) Myostatin protein (4) IGF-1 mRNA | Moxi: Moxibustion BL23 (shenshu), ST36 (zusnali) on both sides 5 times/day every other day for 3 wk Kangwha-moxi cone 0.025g per Ipoint | (1) CSA: Control > CIA+Moxi > CIA (p<0.05) (2) phospho-ERK1/2: CIA > CIA+Moxi (3) Myostatin protein: CIA > CIA+Moxi (4) IGF-1: CIA+Moxi > CIA |
| Kim JW 2015 [13]         | In vivo | Korea  | Total n = 48 Control (8) Dextra control (8) Dextra + OM (8) Dextra + FS125 (8) Dextra + FS250 (8) Dextra + FS500 (8) | Dexamethasone-induced muscle atrophy mice (SPF/VAF mice, n r, n r) | 24 d     | (1) Muscle mass (2) Muscle strength (3) Serum biochemistry (4) Antioxidant defense factor (5) mRNA expression | FS: Fructus Schisandrae extract 125, 250, 500mg/kg, 1/day for 24 d oral intake OM: Oxymetholone 50 mg/kg | (1) Muscle mass (a) Body weight: Dexa < FS125 < FS250 < OM < FS500 (p<0.01) (b) Calf, Gastrocnemius thickness: Dexa < FS125 < FS250 < FS 500 < OM (p<0.01) (2) Muscle strength: Dexa < FS250, FS500 (p<0.01) (3) Serum creatine ↓, CK ↓, LDH ↓ (p<0.01 vs. Control) (4) MDA ↓, ROS ↓, GSH ↑, SOD ↑, CAT ↓ (5) Atrogin-1↓, MuRF1↓, SIRT1↑, PI3K↑, Akt1↑, A1R↑ (p<0.05 vs. control) |
| First Author (year) (Ref) | Design | Origin | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|--------------------------|--------|--------|------------------------|--------------------------|----------|------------------|----------------------------------|--------------|
| Zhang J 2014 [14]       | In vivo | China  | Total n = 45           | Insulin deficiency rat model by low-dose STZ injection (C57BL/6, 12 wk, M) | 6 wk     | (1) Muscle weight | ZB: Zhimu-Huangbai (1:1) herb pair 0.1ml/10g, 1/day for 6 wk | (1) Muscle (quadriceps) weight: ZB > M (p<0.05) |
|                          |        |        | Normal (C) (15)        |                          |          | (2) Muscle function | M: Normal saline treated            | (2) Muscle strength: ZB > M (p<0.01) |
|                          |        |        | Diabetes (M) (15)      |                          |          | (3) Myofiber CSA   | C: Normal saline treated            | (3) CSA: ZB > M (p<0.05) |
|                          |        |        | Diabetes + ZB (15)     |                          |          | (4) IGF1, Akt/mTOR/FoxO3 signal pathways |                                   | (4) IGF-1†, Akt†, mTOR†, p-S6K1†, FoxO3† (p<0.05 vs M) |
| Jang SO 2009 [15]        | In vivo | Korea  | Total n = 48           | Sciatic nerve-damaged rat model (SD rat, 10 wk, M) | 12 d     | (1) Muscle weight | PR: Puerariae Radix extract, 25.0mg/100g, 1/day for 12 d oral intake | (1) Muscle weight: Control < Sample (p<0.05) |
|                          |        |        | Control (24)           |                          |          | (2) Cross-sectional area |                                   | (2) CSA: Control < Sample (p<0.05) |
|                          |        |        | Sample (PR) (24)       |                          |          | (3) Bax, Bcl-2     |                                   | (3) Bcl-2†, Bax † (p<0.05) |
| Kim BH 2016 [16]         | In vivo | Korea  | Total n = 30           | EtOH-treated rat model (SD rat, 10 wk, M) | 8 wk     | (1) Body weight | DKE: Daekumemjja 28.0mg/100g, 1/day for 8 wk | (1) Body weight: EtOH < EtOH + DKE (p<0.05) |
|                          |        |        | Normal (10)            |                          |          | (2) Muscle weight |                                   | (2) Muscle weight: EtOH < EtOH + DKE (p<0.05) |
|                          |        |        | EtOH (10)              |                          |          | (3) Cross-sectional area |                                   | (3) CSA: EtOH < EtOH + DKE (p<0.05) |
|                          |        |        | EtOH + DKE (10)        |                          |          |                                   |                                   |                                   |
| Cho JH 2008 [17]         | In vivo | Korea  | Total n = 36           | Sciatic nerve-damaged rat model (SD rat, 10 wk, M) | 12 d     | (1) Muscle weight | EC: Eucommiae Cortex extract 170mg/100g, 1/day for 12d | (1) Muscle weight: Sham-OP > EC > Control (p<0.05) |
|                          |        |        | Sham-OP (12)           |                          |          | (2) Cross-sectional area |                                   | (2) CSA: Sham-OP > EC > Control (p<0.05) |
|                          |        |        | Control (OP) (12)      |                          |          | (3) Bax, Bcl-2     |                                   | (3) Bax †, Bcl-2 † |
|                          |        |        | OP + EC (12)           |                          |          |                                   |                                   |                                   |
| Lee CW 2007 [18]         | In vivo | Korea  | Total n = 24           | Middle cerebral artery occlusion (MCAO) stroke rat model (SD rat, 10 wk, M) | 25 d     | (1) Muscle fiber type | DR: Dipsaci Radix 18.4 mg/100g, 1/day for 25d, oral intake | (1) Muscle fiber type (type-I): Control < Sample (p<0.01) |
|                          |        |        | Sham (8) Control (MCAO) (8) |                          |          | (2) Cross-sectional area |                                   | (2) CSA: not significant |
|                          |        |        | Sample (MCAO + DR) (8) |                          |          | (3) MHC-II          |                                   | (3) MHC-II† |
|                          |        |        |                          |                          |          | (4) MyoD expression |                                   | (4) MyoD: Control < Sample (p<0.01) |
Table 2: Continued.

| First Author (year) (Ref) | Design | Origin  | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|---------------------------|--------|---------|-------------------------|--------------------------|----------|------------------|-----------------------------------|---------------|
| Han SW 2008 [19]          | In vivo| Korea   | Total n = 18            | MCA occlusion stroke rat model (SD rat, 10 wk, M) | 4 wk     | (1) Muscle fiber type (2) Cross-sectional area (3) MyoD expression | DR: Dipsaci Radix 184.4mg/100g, 1/day for 4 wk, oral intake | (1) Muscle fiber type: type-I ↑, type-II ↓ (p<0.05 vs. control) (2) CSA: control < Sample (p<0.05) (3) MyoD ↑ (p<0.05 vs. control) |
| Kim BH 2017 [20]          | In vivo| Korea   | Total n = 30            | Alcohol-induced (EtOH) muscle atrophy rat model (SD rat, 10 wk, M) | 4 wk     | (1) Muscle weight (2) Cross-sectional area (3) Bcl-2, Bax | PR: Pueraria radix 4.6mg/100g, 1/day for 4 wk, oral intake | (1) Muscle weight: EtOH + PR > EtOH (p<0.05) (2) CSA: EtOH + PR > EtOH (p<0.05) (3) Bcl-2 ↑, Bax ↓ (p<0.05 vs. EtOH) |
| Soh KS 2009 [21]          | In vivo| Korea   | Total n = 24            | Hindlimb suspension rat model (SD rat, 6 wk, M) | 2 wk     | (1) Muscle weight (2) IGF-1 protein (3) Myogenin protein (4) MyoD protein | KS: KangwhalSokdan-tang 1mg/100g, 3 times/1day orally | (1) Muscle weight: HS < HS+KS (p<0.001) (2) IGF-1: HS < HS+KS (p<0.05, in Type I) (3) Myogenin: not significant (4) MyoD: HS < HS+KS (p<0.05 in Type I) |
| Kim BH 2016 [22]          | In vivo| Korea   | Total n = 30            | Alcohol-induced (EtOH) muscle atrophy rat model (SD rat, 10 wk, M) | 4 wk     | (1) Muscle weight (2) CSA (3) Apoptotic factor | SHSGS: Shihosogan-san 31.5 mg/100g, 1/day for 4 wk, orally | (1) Muscle weight not significant (2) CSA: not significant (3) Bcl-2 ↑, Bax ↓ (p<0.05 vs. EtOH) |
| First Author (year) (Ref) | Design | Origin | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|--------------------------|--------|--------|-------------------------|--------------------------|----------|-----------------|----------------------------------|--------------|
| Kim BH 2017 [23]         | In vivo| Korea  | Total n = 20 CON (10) DYJ (10) | Hindlimb suspension rat model (SD rat, 10 wk, M) | 2 wk     | (1) Muscle weight | DYJ: Daeyeoung-jeon 259.6mg/100g/day orally CON: Saline, orally | (1) Muscle weight CON < DYJ (p < 0.05) (2) CSA: CON < DYJ (p < 0.05) (3) Bax↓, Bcl-2↑ (p < 0.05 vs. CON) |
| Kim BH 2017 [24]         | In vivo| Korea  | Total n = 20 CON (10) DGBHT (10) | Hindlimb suspension rat model (SD rat, 10 wk, M) | 2 wk     | (1) Muscle weight | DGBHT: Dangguibohyul-tang 236.7mg/100g/day orally CON: Saline, orally | (1) Muscle weight CON < DGBHT (p < 0.05) (2) CSA: CON < DGBHT (p < 0.01) (3) MDA: no significant difference (4) Cu/Zn-SOD: CON < DGBHT (p < 0.05) |
| Wang D 2017 [25]         | In vivo| China  | Total n = 30 CON (10) JPYS (10) Sham-OP (10) | 5/6 nephrectomized rat model (SD rat, n r-, M) | 6 wk     | (1) Renal function | JPYS: Jian-Pi-Yi-Shen decoction, 10.89mg/kg/day orally | (1) BUN, Creatinine: CON > JPYS (p < 0.001) (2) Muscle weight: CON < JPYS (p < 0.05) (3) CSA: CON < JPYS (p < 0.05) (4) Protein synthesis‡, degradation † (p < 0.05 vs. CON) (5) Atrogin-1†, MuRF-1†, p-FoxO3a†, FoxO3a↓ (p < 0.05 vs. CON) (6) Cox IV†, NRF-1†, PGC-1α↑ (p < 0.05 vs. CON) (7) LC3II/LC3I ratio, Beclin-1†, P62↑, PINK1↑, Parkin protein level↑ (p < 0.05 vs. CON) (8) Fis1↑, Mfn2↑ (p < 0.01 vs CON), Drp-1↑, OPA-1↑ (p < 0.05 vs. CON) |
| Su Z 2017 [26]           | In vivo| China  | Total n = 36 Sham-OP (9) Sham+LFES (9) CKD (9) CKD+LFES (9) | 5/6 nephrectomized rat model (C57/BL6 mice, 2-4 mo, M) | 2 wk     | (1) Autophagosome-proteolysis pathway | LFES: positive point-GB34, negative point-ST36 20Hz, 1mA for 15min | (1) Bnip3↓, Beclin-1↓, LC3II/I ratio↓ (p < 0.05 vs. CKD) |
| First Author (year) | Design | Sample Model Origin | Sample Size (Age / M/F) | Duration | Outcome Measures | Quantity and Type of Intervention |
|---------------------|--------|----------------------|-------------------------|----------|------------------|----------------------------------|
| Zhou L 2018 [27]   | In vivo | China                | Total n = 56           |          |                  |                                  |
|                     |        |                      | Sham-OP (8)            |          |                  | Model > ANGPTL4 siRNA + BYHWT high > BYHWT low (p < 0.05 vs. Model) |
|                     |        |                      | CON+siRNA + BYHWT     |          |                  |                                  |
|                     |        |                      | ANGPTL4-in pathogenesis of DSMA (2x), 2m every day |          |                  |                                  |
|                     |        |                      | DEN 
|                     |        |                      |                |          |                  |                                  |
|                     |        |                      | BYHWT: Yang Huanwu Tang (high: solution diluted 2X, moderate: 4X, low: 8X), 2 ml everyday, orally |          |                  | BYHWT-low (8), BYHWT-moderate (8), BYHWT-high (8) |

**Outcome Measures**

1. **ANGPTL4 in pathogenesis of DSMA**
2. **Muscle cell apoptosis**
3. **NF-κB and MURF1 expression**

**Main outcomes**

- **Inflammatory Cells:**
  - Model: DSMA + saline
  - ANGPTL4: angiopoietin-like protein

**Main outcomes**

- **Denervated-dependent skeletal muscle atrophy**
- **(DSMA)ratmodel (SD rat, 8-10 wk, M)**
- **2 wk**

---

**Yu J 2017 [28]**

| First Author (year) | Design | Sample Model Origin | Sample Size (Age / M/F) | Duration | Outcome Measures | Quantity and Type of Intervention |
|---------------------|--------|----------------------|-------------------------|----------|------------------|----------------------------------|
|                     |        |                      | Total n = 54           |          |                  |                                  |
|                     |        |                      | NOR (6)                |          |                  |                                  |
|                     |        |                      | SNI 1wk, 2wk, 4wk (6 each) |          |                  |                                  |
|                     |        |                      | NOR+EA 4wk, 6wk (6 each) |          |                  |                                  |
|                     |        |                      | Sham-OP (6)            |          |                  |                                  |

**Outcome Measures**

1. **Sciatic nerve functional indices (SFI)**
2. **Muscle weight**
3. **Muscle fibre CSA**
4. **mRNA expression of agrin, AChR-ε and AChR-γ**

**Main outcomes**

- **Sciatic nerve functional indices (SFI):** Model < SNI + EA (p < 0.05)
- **Muscle weight:** Model < SNI + EA (p < 0.05)
- **Muscle fibre CSA:** Model < SNI + EA (p < 0.05)

**EA: Electro-acupuncture**

- **AT36 (positive) and ST36 (negative) 5Hz, 2mA for 30min**
- **1 course: alternatedays, threetimesaweek for 2 weeks**
- **2 course: alternatedays, threetimesaweek for 4 weeks**
- **1 w, 2w, 4w, 6w: euthanased at 1, 2, 4, 6 weeks**

---

**Zhang YH 2017 [29]**

| First Author (year) | Design | Sample Model Origin | Sample Size (Age / M/F) | Duration | Outcome Measures | Quantity and Type of Intervention |
|---------------------|--------|----------------------|-------------------------|----------|------------------|----------------------------------|
|                     |        |                      | Total n = 72           |          |                  |                                  |
|                     |        |                      | SCI (18)               |          |                  |                                  |
|                     |        |                      | TANES (18)             |          |                  |                                  |
|                     |        |                      | EA (18)                |          |                  |                                  |
|                     |        |                      | Sham-OP (18)           |          |                  |                                  |

**Outcome Measures**

1. **Motor neuron of L3, L5**
2. **Neurotransmitter ChAT**
3. **Neurotrophin-3**
4. **Muscle weight**
5. **CSA**

**Main outcomes**

- **Motor neuron of L3, L5:** SCI < TANES, EA (p < 0.05)
- **Neurotransmitter ChAT:** SCI < TANES, EA (p < 0.05)
- **Neurotrophin-3:** SCI < TANES, EA (p < 0.05)
- **Muscle weight:** SCI < TANES, EA (p < 0.05)
- **CSA:** SCI < TANES, EA (p < 0.05)
Table 2: Continued.

| First Author (year) (Ref) | Design | Origin | Group / Sample-Size (n) | Sample Model (Age) (M/F) | Duration | Outcome Measures | Quantity and Type of Intervention | Main outcomes |
|---------------------------|--------|--------|-------------------------|-------------------------|----------|-----------------|-----------------------------------|---------------|
| Zhou L 2017 [30]          | In vivo | China  | Total n = 60<br>Sham-OP (10)<br>Model (10)<br>BYHWT-low (10)<br>BYHWT-middle (10)<br>BYHWT-high (10)<br>MCB (10) | Peroneal nerve injury rat model (SD rat, n, M) | 10d / 21d | (1) NF-κB p65, MuRF1 gene expression in 10day<br>(2) NF-κB p65, MuRF1 gene expression in 21day | BYHWT: Buyang Huanwu Tang<br>(i) low: 3g/kg/day<br>(ii) middle: 6g/kg/day<br>(iii) high: 12g/kg/day<br>MCB: Mecobalamin 500μg/day | (1) NF-κB p65: Model > BYHWT-low > B-middle (p<0.05) > MCB > B-high (p<0.01 vs. model)<br>MuRF1: Model > BYHWT-low > B-middle (p<0.05) > B-high > MCB (p<0.01 vs. model) |
|                           |        |        |                         |                         |          |                 |                                    |               |
| Cao R 2017 [31]           | In vivo | China  | Total n = 63<br>Sham-OP<br>Model<br>EA ∗groups divided into 7days, 14days, 21days each | Sciatic nerve injury rat model (SD rat, 2 mo, M) | 7d / 14d / 21d | (1) Muscle cell apoptosis<br>(2) Apoptotic factor | EA: Electro-acupuncture at ST36 and BL57<br>5Hz, 1.5mA for 10min once a day for 7d, 14d, 21d | (1) Cell apoptosis (7d, 14d, 21d): Model > EA (p<0.05)<br>(2) Bcl-2, Bax, Cyto-C, Caspase-3 in 14d, 21d (p<0.05 vs. Model) |

∗ n r: not reported.
| Authors | Design | Origin | Group / Sample Size (n) | Sample Model | Duration | Outcome Measures | Quantity and Type of Intervention | Main Outcomes |
|---------|--------|--------|-------------------------|--------------|----------|------------------|-----------------------------------|---------------|
| Kim AY 2016 [32] | In vivo/ In vitro | Korea | In vivo: Total n = 20, No tumor (5), Tumor + Saline (5), Tumor + SOSO (5), Tumor + SO100 (5) | In vivo: CT-26 s.c injection tumor-bearing mice (BALB/c mice, 6 wk, M) | In vivo: 18 d | In vivo: (1) Body weight (2) Muscle weight (3) NO, inflammatory cytokines (4) phos-p38, IkBα, IKKaβ, STAT3 | Soshiho-tang (SO) In vivo: (i) SO: fed 50 or 100 mg/kg, days 10 to 27 after tumor inoculation (ii) Control: fed saline | In vivo: (1) Body weight: Normal > T + SO (100) > T + SO (50) > T + Saline (2) Muscle weight: Normal > T + SO (100) > T + SO (50) > T + Saline (3) NO: dose-dependently suppress (p<0.05 vs. control) IL-6, IL-κκ, TNF-α, IL-1β: T + Saline > T + SO (p<0.05) (4) phos-p38 ↑, IkBα ↓, IKKaβ ↓, STAT3↓: T + Saline > T + SO In vitro: (1) IL-6, TNF-α: T + Saline > T + SO (10) > T + SO (50) > T + SO (100) (p<0.05 vs. control) (2) Muscle wasting ↑, Intact myotubes ↓ |
| Authors         | Design     | Origin | Group / Sample Size (n) | Sample Model | Duration | Outcome Measures                                      | Quantity and Type of Intervention | Main Outcomes                                                                 |
|----------------|------------|--------|-------------------------|--------------|----------|------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|
| Zhang ZK 2016  | In vivo/ In vitro | China  | In vivo: Baseline (10) Age-matched control (10) HS (10) L-ICT + HS (10) H-ICT + HS (10) W (10) L-ICT + W (10) H-ICT + W (10) | In vivo: Rats with or without wortmannin inj. (15 \( \mu \text{m/kg/day} \) for 28 d HS (SD rat, 3 mo, M) | In vivo: 28 d | In vivo: (1) Mass outcome (muscle weight, fiber CSA) (2) Muscle function | ICT: Icaritin (L-ICT): 80 mg/kg/day (H-ICT): 120 mg/kg/day, oral intake | In vivo: (1) Mass outcome: HS < L-ICT + HS < H-ICT + HS < Baseline (p<0.05) W < L-ICT + W < H-ICT + W < Baseline (p<0.05) (2) Functional outcome: HS < L-ICT + HS < H-ICT + HS < Baseline (p<0.05) W < L-ICT + W < H-ICT + W < Baseline (p<0.05) |
|                | In vitro   |        | In vitro: Wortmannin (W) pre-incubated C2C12 cell | In vitro: | In vitro: 24 h | In vitro: (1) P13K/Akt signaling proteins | In vitro: ICT 5 \( \mu \text{M} \) or 10 \( \mu \text{M} \) or 20 \( \mu \text{M} \) for 24 h | In vitro: (1) P13K-p110, p-Akt, p-mTOR, p70S6K, p-4EBP1: ICT > ICT+W > W (p<0.05) FOXO1, FOXO3a: ICT < ICT+W < W (p<0.05) Atrogin-1, MuRF-1: ICT < ICT + wort < wort (p<0.05) Atrogin-1, MuRF-1: Control > ICT10 > ICT20 (p<0.05 vs CON) |
| Authors       | Design          | Origin   | Group / Sample Size (n) | Sample Model          | Duration | Outcome Measures | Quantity and Type of Intervention | Main Outcomes |
|---------------|----------------|----------|-------------------------|-----------------------|----------|------------------|-----------------------------------|---------------|
| Sung BK 2015  | In vivo/In vitro| Korea    | In vivo: Young-Control (YC) Young-LE (YL) Old-Control (OC) Old-LE (OL) (n = 4–6 per group) | In vivo: Young SD rat (5 mo, M) Old SD rat (18–19 mo, M) | In vivo: 35 d | In vivo: (1) Muscle mass (2) Muscle function (3) Muscle CK activity | In vivo: Loquat leaf extract (LE) fed 50 mg/kg/day for 35 d | In vivo: (1) Muscle mass: OL > OC (p<0.05) (2) Muscle strength: OL > OC (p<0.05) (3) CK activity: OL > OC (p<0.05) |
|               |                |          | In vitro: CON LE 0.25, 0.5, 1.0, 2.5 myoblasts (untreated) | In vitro: C2C12 viability (2) Myogenic proteins (3) CK activity (4) Akt/mTOR pathway | In vitro: 24 h | In vitro: LE 0.25, 0.5, 1.0, 2.5 µg/ml for 24 h | In vitro: (1) Cell viability: control < LE (2) MyHC, MyoD: control < LE 0.25 < LE 0.5 < LE 1.0 < LE 2.5 (3) CK activity: control < LE 1.0 < LE 2.5 (p<0.01) (4) PI3K, Akt, mTOR: control < LE |
### Table 3: Continued.

| Authors | Design | Origin | Group / Sample Size (n) | Sample Model | Duration | Outcome Measures | Quantity and Type of Intervention | Main Outcomes |
|---------|--------|--------|-------------------------|--------------|----------|------------------|----------------------------------|---------------|
| Lu L 2016 [35] | In vivo/In vitro | China | | | | | | |
| | | | In vivo | Total n = 160 | In vivo: 5/6 nephrectomized SD rats (SD rat, 6 wk, M) | In vivo: 155 d | | | In vivo: Control: Normal diet, Sham OP APS: Normal diet with 2% Astragalus polysaccharide |
| | | | In vivo | | | | | In vivo: (1) Body weight (2) Cross-sectional area (3) p-Akt/mTOR, MuRF1/MAFbx and Autophagy signaling (4) Amino acid carriers (5) Pro-inflammatory & Oxidative factor |
| | | | In vitro | | | | | In vitro: (1) Myotube diameter (2) Akt/mTOR, ubiquitin proteasome, autophagy signaling |
| Lu L 2016 [35] | | | In vitro | | | | | In vitro: APS: 0.05, 0.1, 0.2, 0.5, 1, 2 mg/mL APS 80 ng/mL TNF-α treated |
| | | | In vitro | | | | | In vitro: (1) Myotube diameter: Control < APS (p<0.05) (2) p-mTOR: Control < APS (p<0.05) LC3B-II/LC3B-I ratio: Control > APS (p<0.05) |
| Authors | Design | Sample Size (n) | Sample Model | Duration | Outcome Measures | Quantity and Type of Intervention | Main Outcomes |
|---------|--------|----------------|--------------|----------|------------------|-----------------------------------|-------------|
| Cho SG 2018 [36] | In vivo/ In vitro | In vivo: Total n = 48 normal (8) | In vivo: Hindlimb suspension rat model (SD rats, 6 wk, M) | In vivo: 21 d | In vivo: (1) Muscle weight (2) Muscle strength (3) CSA | SC: Schisandra chinensis (Turcz.) Baill * \( \text{LC: Lycium chinense Mill} \) * \( \text{EU: Eucommia ulmoides Oliv} \) SLE: 2:1:1:1 SC:LC:EU herb pair SLE: 1:1:1 SC:LC:EU | In vivo: (1) Muscle weight (a) Gastrocnemius: CON < SC20 < SC100 < SSLE20 < SSLE100 (p < 0.001 vs CON) (b) Soleus: CON < SC20 < SC100 (p < 0.05) / CON < SSLE20 < SSLE100 (p < 0.001) (c) Tibialis ant: CON < SSLE100 (p < 0.01) (2) Muscle strength: CON < SC100, SSLE20 (p < 0.001), SSLE100 (p < 0.001) (3) CSA: CON < SC100, SSLE20, SSLE100 (p < 0.001) |
| | | | | | | In vitro: (1) Myotube diameter: CON < LC, SC, SLE, SSLE (p < 0.001) (2) atrogin-1 \( \downarrow \) with SC, SLE, SSLE (p < 0.001 vs CON) (3) MuRF-1 \( \downarrow \) with LC, EU, SLE, SSLE (p < 0.001 vs CON) (4) MyoD \( \uparrow \) with LC, EU, SC, SLE, SSLE (p < 0.001 vs CON) (5) Myogenin \( \uparrow \) with EU, SC, SLE, SSLE (p < 0.001 vs CON) (6) p-Akt \( \uparrow \), p-mTOR \( \uparrow \) with LC, EU, SC, SLE, SSLE (p < 0.01 vs CON) |
| | | In vitro: TNF, LC, EU, SC, SLE, SSLE | In vitro: TNF-\( \alpha \) treated C2C12 cell | In vitro: 24 h | In vitro: (1) Myotube diameter (2) Protein synthesis (ubiquitin-proteasome system) | In vitro: 200 \( \mu \)g/ml | |
| Authors     | Design       | Origin | Group / Sample Size (n) | Sample Model                                                                 | Duration       | Outcome Measures                                      | Quantity and Type of Intervention | Main Outcomes                                                                 |
|------------|--------------|--------|-------------------------|-------------------------------------------------------------------------------|----------------|--------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|
| Zhu M 2017 | In vivo/ In  | China  | Total n = 24 CON (8) HS (8) BZ (8) | In vivo: Hindlimb suspension rat model (Kunming mice, 8 wk, M)               | In vivo: 21 d | In vivo: (1) Muscle weight (2) CSA (3) Muscles strength | In vivo: BZ: Bu Zhong Yi Qi decoction 5.93 mg/g/day orally | In vivo: (1) Muscle weight (a) Gastrocnemius: HS < BZ (p < 0.05) (b) Soleus: HS < BZ (p < 0.05) (2) CSA: HS < BZ (p < 0.05) (3) Muscle strength: HS < BZ (p < 0.01) |
|            | vitro        |        |                          |                                                                               |                | In vitro: n r                                          | In vitro:                         |                                                                                   |
|            |              |        |                          |                                                                               |                | In vitro: (1) NCoR1 (nuclear receptor corepressor 1) (2) Myogenesis | In vitro: RS: rat serum BZ: Bu Zhong Yi Qi decoction |                                                                                   |
|            |              |        |                          |                                                                               |                |                                                        |                                   |                                                                                   |
| Geng Z 2017| In vivo/ In   | China  | Total n = 32 NOR (8) CON (8) APS (8) KT (8) | In vivo: 5/6 nephrectomized rat model (SD rat, 7-8 wk, M) | In vivo: 6 wk | In vivo: (1) Atrogin and ubiquitin                     | APS: Astragalus polysaccharide, 3 g/kg/day for 6 weeks, intraperitoneally in vitro: 15 mg/l KT: ketosteril (α-ketoacid tablets), 1 ml/200 g/day for 4 weeks, intravenously CON: saline, 3 g/kg/day for 6 weeks, intraperitoneally NOR: Sham-OP | In vivo: (1) Atrogin-1: APS < KT < CON (p < 0.05 vs CON) Ubiquitin: APS < KT < CON (p < 0.05 vs CON) |
|            | vitro        |        |                          |                                                                               |                |                                                        |                                   |                                                                                   |
|            |              |        |                          |                                                                               |                |                                                        |                                   |                                                                                   |
| Authors | Design | Group / Sample Size | Sample Origin | Group / Sample Size | Sample Origin | Group / Sample Size | Sample Origin | Outcome Measures | Quantity and Type of Intervention | Main Outcomes |
|---------|--------|---------------------|---------------|---------------------|---------------|---------------------|---------------|-----------------|----------------------------------|--------------|
| Kim AY 2018 [39] | In vivo/ In vitro | CT-26 colon carcinoma-implanted mice | Korea | In vivo: C57BL/6 mice, 6 wk, M | | In vivo: 15 d | | In vivo: | | (1) Body weight; CON < SGE10 (p < 0.05), SGE20 (p < 0.05), SGE50 (p < 0.05) | |
| | | Total n = 15 | | | | | | | | (2) Muscle weight | |
| | | CON (5) | | | | | | | | (3) IL-6 | |
| | | SGE 10 (5) | | | | | | | | SGE: herbal cocktail composed of Ginseng Radix alba, Atractylodis Rhizoma alba, and Hoelen | |
| | | SGE 50 (5) | | | | | | | | In vivo: SGE 10 mg/kg/day, or 50 mg/kg/day for 15 days, orally | |
| Tseng YT 2017 [40] | In vivo/ In vitro | CT-26 colon carcinoma-implanted mice | China | | | | | | | (1) Body weight; CON < LWHD30 (p < 0.001) | |
| | | Total n = 32 | | | | | | | | (2) Hindlimb score: CON < LWHD30 (p < 0.001) | |
| | | WT (15) | | | | | | | | (3) Body weight: WT > LWHD30 (p < 0.001) | |
| | | LWHD30 (8) | | | | | | | | LWHD15 (8) | |
| | | SGE 0.01, 0.1, 1, 10 μg/mL | | | | | | | | (1) Survivin expression in muscle | |
| | | (2) TNF-α expression in muscle | | | | | | | | LWHD30 (p < 0.001) | |
| | | | | | | | | | | LWHD15 (p < 0.05) | |
| | | | | | | | | | | NOS1 (25, 50, p < 0.001), iNOS (25, 50, p < 0.001), p-p38 (25, 50, p < 0.001), p-ERK (25, 50, p < 0.001), p-JNK (25, 50, p < 0.001) | |
| | | | | | | | | | | p-IκBα (25, 50, p < 0.001) | |
| | | | | | | | | | | MyHC (25, 50, p < 0.001) | |
(F) Tumor-Induced Model. All the tumor model studies measured markers of the immune system, such as TNF-α and interleukins. In the study by Kim AY et al., Sosho-tang suppressed the production of cachexia-inflammatory cytokines (IL-6, IL-1, and TNF-α) and these inhibited the activation of nitric oxide and p38, NF-κB, and STAT3, thereby reducing muscle loss [32]. Another study by Kim AY et al., a novel herbal formula, SGE, also decreased inflammatory cytokines [39] and Zhuang et al. found that the Zhimu-Huangbai (1:1) herb pair reduced tumor-induced muscle loss and inhibited cachectic cytokines [8].

(G) Dexamethasone or Alcohol-Induced Model. Kim et al. found a statistically significant inhibition of muscle loss in the dexamethasone-induced muscle atrophy model after treating with Fructus Schisandraceae by the activation of SOD, CAT, and GSH [13]. Furthermore, Kim et al. treated with Radix Pueraria extract and Shihosogan-san (SHSGS), both of which inhibited muscular atrophy by inhibiting Bax and promoting PGC-1α and GSH [13]. Furthermore, Kim et al. treated with Radix Pueraria extract and Shihosogan-san (SHSGS), both of which inhibited muscular atrophy by inhibiting Bax and promoting PGC-1α and GSH [13].

(H) The Others. In a study by Yuki Kishida et al., Gosha-jinki-Gan (GIG) was administrated to a senescence-accelerated mouse which promoted pAMPK and PGC-1α, thereby activating mitochondrial neogenesis and oxidative metabolism [9].

Yuya Nakashima et al. demonstrated that significant decreases in muscle loss and oxidative stress due to the reduction of malondialdehyde (MDA) and 4-hydroxynonenals (HANE) of muscle cells occurred after treating with Chlorella extract [11].

In Zhang YT et al., spinal cord injury-induced (SCI) muscular atrophy model was treated with E-AT [29]. E-AT increased the expression levels of choline acetyltransferase (ChAT), which is a transferase enzyme responsible for the synthesis of the excitatory neurotransmitter acetylcholine [50]. Likewise, E-AT increased the protein neurotrophin-3 (NT-3), a member of the neurotrophin family, and has an important role in neuroprotection and axonal regeneration [51]. Through these mechanisms, E-AT on SCI rat protected the motor neurons as well as alleviated muscular atrophy.

Tseng YT et al. using spinal muscular atrophy rat model, Liuwei dihuang water extract (LWDH-WE) improved muscle strength and body weight accompanied by upregulation of survival motor neuron protein in spinal cord and gastrocnemius muscle tissues [40].

3.3. In Vitro Studies. A total of 17 (8 in vitro only, 9 in vivo with in vitro) articles were classified as in vitro studies in this review.

3.3.1. Muscle Cell Model. C2C12 cells (myoblasts and myotubes) were used in 15 of the 17 studies. There was 1 study using L6 myoblasts and 1 using NSC34 motor neuron-like cells. The TNF-α-induced apoptosis and autophagy model were used in 4 studies, while the oxidative stress model was used in 3 studies. In addition to these, 3 studies utilized the no treatment model, 2 using cancer model. The dexamethasone-treated, PI3K-p110-suppressed, AICAR-treated, starvation-induced, and transgenic models were used in 1 study each (Figure 4).

3.3.2. Interventions. All 17 studies used herbal medicine as the intervention method. The treatment period spanned 24 hours in 8 studies, 48 hours in 7 studies, and 72 hours in 1 study. One study did not report the treatment period.

3.3.3. Outcomes. Myotube diameter and muscle cell number were set as the primary outcomes. In most studies, significant increases in both the diameter of myotubes and muscle cell numbers were reported (Tables 3 and 4).

(A) Oxidative Stress Model. In the three studies using the oxidative stress model, Jung et al. found that idesolide extract protected muscle cells from oxidative stress by promoting the activation of heat shock protein 70 (HSP70) in the cells [42]. HSP70 protects cells from a number of apoptotic stimuli, including oxidative stress and is significantly downregulated in various models of skeletal muscle atrophy [52]. They also found the same effects when sauchinone (root of Saussurea chinensis) was used as the mode of treatment [44].

In Choe YH., isorhamnetin (ISO) extract was treated to hydrogen peroxide- (H2O2-) induced oxidation damaged muscle cells. In general, H2O2 causes cell apoptosis with mitochondrial damage and ROS generation by upregulation of Bax and downregulation of Bcl-2 [53]. The ISO extract inhibited the apoptosis by the restoration of Bax, Bcl-2 proteins, and decreasing of caspase-9 and caspase-3. In addition, the ISO activated the antioxidant protein heme oxygenase-1 (HO-1) and its transcription factor, nuclear factor erythroid derived 2-related factor 2 (Nrf2), thereby suppressing oxidative stress [47].

(B) AICAR-Induced Model. Kang et al. found that the administration of Schisandraceae Fructus (SF) extract to AICAR (5-aminoimidazole-4-carboxamide-ribonucleotide)-induced muscle atrophy C2C12 myotubes significantly counteracted AICAR-induced muscle cell atrophy and reversed the increased expression of MuRF-1 and FoxO3a [46]. AICAR is an enzyme that upregulates MuRF-1 and stimulates the levels of the FoxO3a transcription factor [54]. SF extract could reverse the muscle cell atrophy caused by AICAR through regulation of the AMPK and FoxO3a signaling pathways, followed by inhibition of MuRF-1.
Table 4: Summary of articles on complementary and alternative medicine therapies for muscular atrophy (in vitro).

| Authors       | Design  | Origin | Group / Sample-Size (n) | Sample Model                                      | Duration | Outcome Measures                                                                 | Quantity and Type of Intervention | Main Outcomes                                                                 |
|---------------|---------|--------|-------------------------|---------------------------------------------------|----------|----------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|
| Lu L 2013 [41] | In vitro | China  | Control DEX DEX + APS APS | Dexamethasone (DEX) or peroxide-induced atrophy C2C12 cells | 24 h     | (1) Myotube diameter  
(2) Akt/mTOR activation  
(3) PTP1B expression and activity  
(4) Myoblasts proliferation  
(5) Anti-apoptosis  
(6) Apoptosis related protein expression | 0.2 mg/mL Astragalus polysaccharide (APS) | (1) Muscle fiber diameter: DEX + APS > DEX (p<0.05)  
(2) p-Akt↑, p-P70s6k↑, p-mTOR↑, p-rpS6↑ (p<0.05 vs. DEX)  
(3) PTP1B expression & activity: DEX > DEX + APS (p<0.05)  
(4) Proliferation rate: 50 μg/mL < 0.1 mg/mL < 0.2 mg/mL (p<0.05 vs. Control (Con))  
(5) Apoptotic cells: H2O2 > H2O2 + APS (p<0.05)  
(6) Caspase-8, Caspase-3: H2O2 > H2O2 + APS  
Bcl-2: H2O2 < H2O2 + APS (p<0.05)  
Bax: H2O2 > H2O2 + APS (p<0.05) |
| Jung MH 2010 [42] | In vitro | Korea  | Control H2O2 + IDS 1 μM H2O2 + IDS 5 μM H2O2 + IDS 10 μM H2O2 + IDS 25 μM H2O2 + NAC 5 mM | C2C12 cell-cultured with H2O2 (0.1, 0.5, 1, 2, 4 mM) | 24 h     | Pre-treatment with Idesolide: cultured for 24 hr with 1, 5, 10, 25 μM idesolide or without idesolide |                                | (1) Cell viability: Con < IDS 5 μM < 25 μM < 5 μM < 10 μM (p<0.001 vs. Con)  
Con < NAC 5 μM < IDS 25 μM (p<0.001 vs. Con)  
(2) HSP70: H2O2 < H2O2 + IDS (p<0.001) |
| Authors         | Design | Origin | Group / Sample-Size (n) | Sample Model | Duration | Outcome Measures                                                                 | Quantity and Type of Intervention | Main Outcomes                                                                 |
|-----------------|--------|--------|-------------------------|--------------|----------|---------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------------|
| Takeda T        | In vitro | Japan  | Control HJG 1 µg/mL, HJG 10 µg/mL, HJG 50 µg/mL, HJG 100 µg/mL, HJG 200 µg/mL | C2C12 myoblasts (untreated) | 3 d      | (1) Cell proliferation (2) ERK1/2 phosphorylation (3) Akt activity (4) Differentiation of cells | Hachimijiogan (HJG): 1~200 µg/mL for 3 d | (1) Cell number: HJG (1, 10, 50, 100, 200) > Control (p<0.05) (2) ERK1/2 activity: HJG200 > Control (2.89 fold, p<0.0001) (3) Akt activity: Not significant (4) Cell differentiation: Not significant |
| Jung MH         | In vitro | Korea  | Untreated H2O2, H2O2 + Sau 10, H2O2 + Sau 25, H2O2 + Sau 50, H2O2 + NAC | H2O2 treated C2C12 cell | 24 h     | (1) Cell viability (2) HSP expression (3) Ceramide content | Sauchinone (Sau): cultured for 24 hr with 10, 25, 50 µM | (1) Cell viability: H2O2 + Sau > H2O2 + NAC > H2O2 (p<0.01) (2) HSP 70 expression: H2O2 + Sau > H2O2 (p<0.01) (3) Ceramide: H2O2 > H2O2 + Sau (p<0.01) |
| Chen D          | In vitro | China  | Control TNF-α, TNF-α + ED 5 µM, TNF-α + ED 10 µM, TNF-α + ED 20 µM | TNF-α-induced apoptosis and autophagy C2C12 myoblast | 24 h     | (1) Anti-apoptosis (2) Mitochondrial pathway (3) Autophagy (4) p-Akt activation | Emodin (ED): component of Rheum palmatum 5, 10, 20 µM | (1) Apoptotic cells: TNF > TNF + ED20 > TNF + ED10 (p<0.05) (2) Bcl-2/Bax↑, cleaved-caspase 3↑, cleaved-PARP↑ (p<0.05) (3) LC3↑, Beclin-1↑, Atg7↓ (p<0.05 vs. TNF) (4) p-Akt↑ (p<0.05 vs. TNF) |
| Kang YS         | In vitro | Korea  | Control SF 100, SF 200, AICAR, AICAR + SF100, AICAR + SF200 | AICAR-induced muscle atrophy C2C12 myotubes | 2 d      | (1) Myoblast differentiation (2) Muscle atrophy markers | Schisandrae fructus (SF): Extract of the fruits of Schisandra chinensis Bailon 100, 200 µg/mL | (1) Myosin-heavy-chain↑, Myogenin↑ (2) FoxO3a, MuRF-1, AMPK↓; AICAR > AICAR + SF100 > AICAR + SF200 |
| Authors      | Design | Origin | Group / Sample-Size (n) | Sample Model | Duration | Outcome Measures | Quantity and Type of Intervention | Main Outcomes |
|--------------|--------|--------|-------------------------|--------------|----------|------------------|-----------------------------------|---------------|
| Choe YH 2015 [47] | In vitro | Korea | Normal H2O2 ISO H2O2 + ISO | H2O2 (1 mM) treated C2C12 cell | 24 h | (1) Anti-oxidative stress effect (2) Anti-apoptosis (3) ROS marker (4) Bcl-2, Bax level (5) Caspase activity (6) Nrf2/HO-1 | Isorhamnetin (ISO): a flavonoid derived from Hippophae rhamnoides L. 30 μM | (1) Cell viability: H2O2 < H2O2 + ISO (2) Anti-apoptosis: H2O2 < H2O2 + ISO (3) ROS: H2O2 > H2O2 + ISO (inhibit 64% vs. H2O2) (4) Bcl-2↑, Bax↓ (5) Caspase-9, Caspase-3: H2O2 > H2O2 + ISO (p<0.05) (6) Nrf2↑, HO-1↑ |
| Li F 2017 [48] | In vitro | China | CON SF Rgl 10⁻⁴ Rgl 10⁻³ Rgl 10⁻² Rgl 10⁻¹ | Starvation induced muscle protein degradation C2C12 myoblast | 48h | (1) Atrogin-1 and MuRF-1 expression (2) PI3K-dependent phosphorylation of AKT, FoxO and mTOR | SF: Serum-free medium for 48h incubation (Starvation induced) Rgl: Ginsenoside Rgl 10⁻¹, 10⁻², 10⁻³ and 10⁻⁴ mM. incubate for 48h | (1) Atrogin-1: SF > Rgl 10⁻¹ > Rgl 10⁻² > Rgl 10⁻³ > Rgl 10⁻⁴ (p<0.05 vs. SF) MuRF-1: SF > Rgl 10⁻⁴ > Rgl 10⁻³ > Rgl 10⁻² (p<0.05 vs. SF) (2) p-FoxO1↑, p-FoxO3α↑, p-Akt↑, p-mTOR↑ (p<0.05) |
(C) TNF-α-Induced Model. In Lu L. et al., the ratio of phosphorylated mTOR to total mTOR was decreased, whereas the ratio of LC3B-II to LC3B-I increased after TNF-α treatment. APS restored the downregulation of p-mTOR and increased the ratio of LC3B-II to LC3B-I [35]. In Chen D. et al. using Emodin (ED) to TNF-α treated C2C12 myoblasts, ED significantly attenuated mitochondrial signaling pathways related cell apoptosis by increasing of Bcl-2 and decreasing of Bax, cleaved caspase-3 and cleaved-PARP. In addition, ED inhibited autophagy by suppressing the expression of LC3-III, Beclin-1, and Atg7 [45].

In the study by Cho SG et al., herbal formula consisting of Schisandra chinensis Baill, Lycium chinense Mill, and Eucommiaulmoides Oliv significantly inhibited protein degradation by decreasing atrogin-1 and MuRF-1 and promoted synthesis by stimulating Akt/mTOR signaling pathway. The formula also increased MyoD and myogenin [36]. Geng Z et al. used APS and pyrrolidine dithiocarbamate (PDTC) to TNF-α treated L6 myoblasts. Both extracts delayed muscle cell atrophy through reducing atrogin-1 and ubiquitin [38].

(D) Untreated Model. In the studies using the untreated C2C12 myoblast model, Takeda et al. showed that administration of Hachimijioogan (HJG) to untreated C2C12 cells promoted muscle cell proliferation through activation of ERK1/2 signaling pathway without affecting the Akt signaling pathway [43]. In a study by Sung BK et al., the expression levels of myogenic proteins (MyoD and myogenin) and functional myosin heavy chain (MyHC) were measured to evaluate the myogenic potential of loquat leaf extract (LE). LE enhanced those proteins and also activated the PI3K-Akt/mTOR signaling pathway [34]. In Zhu M. et al., the results indicated that Bu Zhong Yi Qi decoction (BZ) significantly downregulated NCoR1 expression and further induced muscle differentiation and metabolism by regulating NCoR1-associated gene expression [37].

(E) Tumor-Mediated Model. Kim AY et al. found that soshohingt decreased serum IL-6 levels and TNF-α [32]. In another study by Kim AY et al., herbal formula, SGE also reduced IL-1β, IL-6, and TNF-α [39].

(F) The Others. In Zhang’s study using PI3K-p110-suppressed C2C12 cells, icaritin extract promoted the expression of PI3K-Akt signaling markers [33].

Lu L. et al. reported in a study using the dexamethasone-induced muscle cell injury model that APS increased p-Akt, p-mTOR, p-P70s6k, and p-rsS6 and inhibited FoxO3a/FoxO1 [41].

In Tseng YT et al., inducible survival motor neuron-knockdown NSC34 motor neuron-like cells were used to mimic survival motor neuron- (SMN-) deficient condition. LWDH-WE significantly increased mitochondrial membrane potential and suppressed apoptosis by attenuating the SMN deficiency-induced downregulation of Bcl-2 and upregulation of cytosolic cytochrome c and cleaved caspase-3 [40].

In Li P et al., starvation-induced muscle protein degradation model by incubation of the cells with serum-free basal medium was treated with ginsenoside Rgl. The Rgl inhibited MuRF-1 and atrogin-1 and also activated the p-mTOR, Akt, p-FoxO1, and p-FoxO3a [48].

4. Discussion

As the threat of the global aging phenomenon rises, there has been a growing interest in healthy aging, which in turn has led to an increased interest in muscular atrophy and sarcopenia within the medical community.

Recently, many clinical cases, trials, and preclinical studies have been conducted on the effect of CAM on muscular atrophy; however, a review of the study results and treatment mechanisms reported has been inadequate. We performed the review to establish clinical evidence and suggest a direction for future research in finding treatment mechanisms.

As the results showed, the hindlimb suspension and nerve damaged models were most commonly used in the in vivo studies, which are preferred because they can be induced muscle atrophy by directly and mechanically. CKD model, cancer model, stroke model, and diabetes model were useful for studying muscle atrophy that results from comorbidity of several common diseases.

In many studies, to find the mechanisms of action of muscular atrophy treatment, various markers of muscle protein synthesis and muscular atrophy inhibitors were measured.

In the majority of studies including our review, PI3K-Akt-mTOR signaling pathway factors were investigated. The activation of PI3K leads to activation of the serine/threonine kinase Akt, which in turn phosphorylates and activates its downstream proteins (mTOR, p70S6K, 4EBP1, and eIF4E) and resulted in increased protein synthesis and led to skeletal muscle hypertrophy [55, 56]. Mammalian target of rapamycin (mTOR) which is activated by PI3K-Akt signaling pathway functions as a protein kinase that directly influence cell growth and protein synthesis [57]. As the above markers are included in the major pathways in muscular atrophy, these are suggested to be measured in the related studies.

In addition, other cell proliferation pathway proteins like TRPV4, ERK1/2 could be investigated. TRPV4, a member of the TRP channel superfamily, is known to promote physiological functions in muscle [58], and ERK1/2 is member of the mitogen-activated protein kinase super family that can mediate cell proliferation and apoptosis in the Ras–Raf–MEK–ERK signaling cascade [59].

MuRF1 and FoxO3/atrogin-1 are proteins leading to upregulation of the UPS pathway to catalyze the myofibrillar proteins [60]. FoxO3 can be phosphorylated by Akt, and deactivation of Akt would lead to relocation of FoxO into the nucleus and activate atrophy-induced genes. Activated FoxO3 stimulates lysosomal proteolysis in muscle by activating the autophagy process by transcriptional regulation [61]. So, these proteins are needed to find the activation of UPS pathway in muscle atrophy.

In the cell apoptotic markers, Bax, a proapoptotic factor that promotes cell death, and Bcl-2, an antiapoptotic factor, were mainly used. Caspase-9 and caspase-3 were also measured because they were the key caspase proteases in...
the activation of intrinsic apoptosis pathway [62]. Through the measurement of those apoptotic factors, the efficacy of suppressing muscle cell apoptosis can be verified. MyoD, MHC-II, MyHC, and myogenin were measured to investigate the level of myogenesis. MyoD, MHC-II, and MyHC are proteins that play a major role in regulating muscle differentiation, and myogenin is a transcription factor involved in coordination of skeletal muscle development or myogenesis and repair.

Mitochondria related proteins like PGC-1α, Cox IV, and NRF-1 were measured to investigate the effect of skeletal muscle metabolism through modulating mitochondrial biogenesis. Also, NCoR1 were measured as a key modulator of the mitochondrial metabolism in muscle, which can reprogram muscle metabolism from a glycolytic to a more oxidative mitochondrial state [63].

In this literature review, we searched for articles on CAM as a treatment modality for muscular atrophy. However, owing to the small number of studies used in the review, only a qualitative analysis of the data could be done. Further studies must be carried out to provide additional evidence to support our findings.

5. Conclusion

In this study, outcome measures of muscle mass and function were used to evaluate the effects of complementary and alternative medicine on muscular atrophy and, in most of studies, the results have proven it to be significantly effective. Markers of muscle protein synthesis and muscle atrophy inhibitors were measured to find their treatment mechanisms. In those mechanisms, (1) changes in growth hormone/IGF productivity and sensitivity by aging, (2) decrease of muscle protein by proinflammatory cytokines (TNF-α, IL-1, IL-6, etc.), (3) acceleration of apoptosis in muscle cells, (4) ubiquitin-proteasome proteolytic pathway, and (5) Akt/mTOR signaling pathway were found to be important factors contributing to treatment effects.

In most of the studies we have investigated, CAM promoted protein synthesis and inhibited degradation by enhancing the PI3K-Akt-mTOR signaling pathway. It also inhibited the ubiquitin-proteasome system which was involved in protein degradation. In several studies, CAM alleviated skeletal muscle metabolism through modulating mitochondrial biogenesis factors, thereby preventing muscle loss. In addition, CAM restored the expression of proteins involved in the cell apoptotic pathway and autophagy pathway in the various models of muscular atrophy.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Yong-Hyeon Baek is responsible for developing the research strategy and data extraction form, supervising the research fulfillment, and drafting the manuscript. Byung-Kwan Seo contributed to developing the research strategy and drafting the manuscript. Seong-Mok Jeong is responsible for searching articles, developing data extraction form, extracting data, and drafting the manuscript. Yeon-Cheol Park contributed to analyzing articles and extracting data. All authors have read, revised, and approved the final manuscript. Seong-Mok Jeong and Byung-Kwan Seo contributed equally to this work.

Acknowledgments

This research was supported by the Basic Science Research Program, through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2016R1D1A1B03930503).

References

[1] W. R. Frontera and J. Ochala, "Skeletal muscle: a brief review of structure and function," Behavior Genetics, vol. 45, no. 2, pp. 183–195, 2015.
[2] S. Cohen, J. A. Nathan, and A. L. Goldberg, "Muscle wasting in disease: molecular mechanisms and promising therapies," Nature Reviews Drug Discovery, vol. 14, no. 1, pp. 58–74, 2015.
[3] V. Malafarina, F. Uriz-Otano, R. Iniesta, and L. Gil-Guerrero, "Effectiveness of Nutritional Supplementation on Muscle Mass in Treatment of Sarcopenia in Old Age: A Systematic Review," Journal of the American Medical Directors Association, vol. 14, no. 1, pp. 10–17, 2013.
[4] A. J. Cruz-Jentoft, J. P. Bayens, J. M. Bauer et al., "Sarcopenia: European consensus on definition and diagnosis," Age and Ageing, vol. 39, no. 4, Article ID eaf034, pp. 412–423, 2010.
[5] A. Onda, Q. Jiao, Y. Nagano et al., "Acupuncture ameliorated skeletal muscle atrophy induced by hindlimb suspension in mice," Biochemical and Biophysical Research Communications, vol. 410, no. 3, pp. 434–439, 2011.
[6] Z. Su, A. Robinson, L. Hu et al., "Acupuncture plus low-frequency electrical stimulation (Acu-LFES) attenuates diabetic myopathy by enhancing muscle regeneration," PLoS ONE, vol. 10, no. 7, Article ID e0134511, 2015.
[7] Y. Dong, Y. Li, Y. Sun et al., "Bufei Jianpi granules improve skeletal muscle and mitochondrial dysfunction in rats with chronic obstructive pulmonary disease," BMC Complementary and Alternative Medicine, vol. 15, no. 1, 2015.
[8] P. Zhuang, J. Zhang, Y. Wang et al., "Reversal of muscle atrophy by Zhimu and Huangbai herb pair via activation of IGF-1/Akt and autophagy signal in cancer cachexia," Supportive Care in Cancer, vol. 24, no. 3, pp. 1189–1198, 2016.
[9] Y. Kishida, S. Kagawa, and J. Arimitsu, "Go-sha-jink-Gan (GJJ), a traditional Japanese herbal medicine, protects against sarcopenia in senescence-accelerated mice," Phytomedicine, vol. 22, no. 1, pp. 16–22, 2015.
[10] L. Hu, J. D. Klein, F. Hassounah et al., "Low-frequency electrical stimulation attenuates muscle atrophy in CKD—a potential treatment strategy," Journal of the American Society of Nephrology, vol. 26, no. 3, pp. 626–635, 2015.
[11] Y. Nakashima, I. Ohsawa, K. Nishimaki et al., "Preventive effects of Chlorella on skeletal muscle atrophy in muscle-specific mitochondrial aldehyde dehydrogenase 2 activity-deficient mice," BMC Complementary and Alternative Medicine, vol. 14, article 390, 2014.
[12] M. Kim, U. Namgung, and K. Hong, “Regenerative Effects of Moxbustion on Skeletal Muscle in Collagen-Induced Arthritic Mice,” *Journal of Acupuncture and Meridian Studies*, vol. 5, no. 3, pp. 126–135, 2012.

[13] J. W. Kim, S.-K. Ku, M. H. Han et al., “The administration of Fructus Schisandrae attenuates dexamethasone-induced muscle atrophy in mice,” *International Journal of Molecular Medicine*, vol. 36, no. 1, pp. 1–9, 2015.

[14] J. Zhang, P. Zhuang, Y. Wang et al., “Reversal of muscle atrophy by Zhihu-Huangbai herb-pair via Akt/mTOR/FoxO3 signal pathway in streptozotocin-induced diabetic mice,” *PLoS ONE*, vol. 9, no. 6, article e009918, 2014.

[15] SO. Jang and YS. Kim, “Effect of Puerariae Radix on Hind Limb Muscle Atrophy of Sciatic Nerve Transectioned Rats,” *Kor J Orient Physiol Pathol*, vol. 23, no. 2, pp. 405–411, 2009.

[16] B. H. Kim, “The Effects of Daekumeumjung on Alcohol-induced Muscle Atrophy in Rats,” *Herbal Formula Science*, vol. 24, no. 3, pp. 153–161, 2016.

[17] JH. Cho, KS. Kim, and JD. Cha, “Effect of Eucommiae Cortex on Hind Limb Muscle Atrophy of Sciatic Nerve Transectioned Rats,” *Kor J Orient Physiol Pathol*, vol. 22, no. 6, pp. 1454–1461, 2008.

[18] S. Y. Jung and M. J. Lee, “The effects of Ohyakusun-kisan (Wuyaoqunqisan) on increasing body fat of rat induced by high fat diet,” *Journal of Oriental Rehabilitation Medicine*, vol. 17, no. 4, pp. 23–29, 2007.

[19] SW. Han, SH. Ryu, and ES. Shim, “Effects of Dipsaci Radix on Muscle Fiber Atrophy and MyoD Expression in Rats,” *Atherosclerosis*, vol. 221, no. 1, pp. 1–7, 2017.

[20] B. H. Kim, “The Protective Effects of Pueraeradix against Chronic Alcohol-induced Muscle Atrophy in Rats,” *Journal of Korean Medicine Rehabilitation*, vol. 27, no. 2, pp. 1–8, 2017.

[21] KS. Soh, YH. Park, and OhJK, “The Effect of KangwhaSiokdandan (jianghuoxuduan-tang) Administration on Muscle Regeneration in Atrophied Rat Muscle Induced by Hindlimb Suspension,” *J Oriental Rehab Med*, 2009.

[22] B. H. Kim, “The Effects of Shihosogasan on Alcohol-induced Muscle Atrophy in Rats,” *Herbal Formula Science*, vol. 24, no. 4, pp. 311–321, 2016.

[23] BH. Kim, “The effect of Daeyeoung-jeon on the prevention of disuse muscle atrophy in rats,” *Korean Med Rehab*, vol. 25, no. 4, pp. 499–508, 2017.

[24] B. H. Kim, “The Protective Effects of Dangguibohyul-tang (Dangguibuxuetang) against Disuse Muscle Atrophy in Rats,” *Journal of Korean Medicine Rehabilitation*, vol. 27, no. 4, pp. 1–9, 2017.

[25] D. Wang, J. Chen, X. Liu et al., “A Chinese herbal formula, Jian-Pi-Yi-Shen decoction, improves muscle atrophy via regulating mitochondrial quality control process in 5/6 nephrectomised rats,” *Scientific Reports*, vol. 7, no. 1, 2017.

[26] Z. Su, J. D. Klein, J. Du et al., “Chronic kidney disease induces autophagy leading to dysfunction of mitochondria in skeletal muscle,” *American Journal of Physiology-Renal Physiology*, vol. 312, no. 6, pp. F1128–F1140, 2017.

[27] L. Zhou, Y. Huang, H. Xie, and X. Mei, “Buyang Huanwu Tang improves denervation-dependent muscle atrophy by increasing ANGPTL4, and increases NF-κB and MURF1 levels,” *Molecular Medicine Reports*, vol. 17, no. 3, pp. 3674–3680, 2018.

[28] J. Yu, M. Wang, J. Liu, X. Zhang, and S. Yang, “Effect of electroacupuncture on the expression of agrin and acetylcholine receptor subtypes in rats with tibialis anterior muscular atrophy induced by sciatic nerve injection injury,” *Acupuncture in Medicine*, vol. 35, no. 4, pp. 268–275, 2017.

[29] Yu-Ting Zhang, Hui Jin, Jun-Hua Wang et al., “Tail Nerve Electrical Stimulation and Electro-Acupuncture Can Protect Spinal Motor Neurons and Alleviate Muscle Atrophy after Spinal Cord Transsection in Rats,” *Neural Plasticity*, vol. 2017, Article ID 7351238, 11 pages, 2017.

[30] L. Zhou and XY. Mei, “Effect of Buyang Huanwu decoction on NF-κB/MURF-1 expression in rats with denervated tibial muscle atrophy,” *China J of Chinese Materia Medica*, vol. 42, no. 9, pp. 1762–1765, 2017.

[31] R. Cao, C. Tang, and S. Huang, “Effects of Electroacupuncture on Apoptosis-related Protein Expression of Gastrocnemius Muscle Cells in Rats with Denervated Sciatic Nerve,” *Journal of Acupuncture Research*, vol. 42, no. 4, pp. 302–307, 2017.

[32] A. Kim, M. Im, and J. Y. Ma, “Sosisho-tang ameliorates cachectia-related symptoms in mice bearing colon 26 adenocarcinoma by reducing systemic inflammation and muscle loss,” *Oncology Reports*, vol. 35, no. 3, pp. 1841–1850, 2016.

[33] Z.-K. Zhang, J. Li, J. Liu et al., “Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading,” *Scientific Reports*, vol. 6, 2016.

[34] B. Sung, S. Y. Hwang, M. J. Kim et al., “Lomat leaf extract enhances myogenic differentiation, improves muscle function and attenuates muscle loss in aged rats,” *International Journal of Molecular Medicine*, vol. 36, no. 3, pp. 792–800, 2015.

[35] L. Lu, Y. Huang, D. Chen et al., “Astragalus polysaccharides decrease muscle wasting through Akt/mTOR, ubiquitin proteasome and autophagy signalling in 5/6 nephrectomised rats,” *Journal of Ethnopharmacology*, vol. 186, pp. 125–135, 2016.

[36] S. Cho, R. Hong, P. Yim et al., “An herbal formula consisting of Schisandrae chinensis (Turcz.) Baill, Lycium chinense Mill and Eucommia ulmoides Oliv alleviates disuse muscle atrophy in mice,” *Journal of Ethnopharmacology*, vol. 213, pp. 328–339, 2018.

[37] M. Zhu, Z. Liu, M. Gao et al., “The effect of Bu Zhong Yi Qi decoction on simulated weightlessness-induced muscle atrophy and its mechanisms,” *Molecular Medicine Reports*, vol. 16, no. 4, pp. 5165–5174, 2017.

[38] Z. Geng, L. Wei, C. Zhang, and X. Yan, “Astragalus polysaccharide, a component of traditional chinese medicine, inhibits muscle cell atrophy (Cachexia) in an in vivo and in vitro rat model of chronic renal failure by activating the ubiquitin-proteasome pathway,” *Experimental and Therapeutic Medicine*, vol. 14, no. 1, pp. 91–96, 2017.

[39] A. Kim, M. Im, and J. Y. Ma, “A novel herbal formula, SGE, induces endoplasmic reticulum stress-mediated cancer cell death and alleviates cachexia symptoms induced by colon-26 adenocarcinoma,” *Oncotarget*, vol. 9, no. 23, pp. 16284–16296, 2018.

[40] Y.-T. Tseng, Y.-J. Jong, W.-F. Liang, F.-R. Chang, and Y.-C. Lo, “The water extract of Liuwei dihuang possesses multi-protective properties on neurons and muscle tissue against deficiency of survival motor neuron protein,” *Phytotherapy Research*, vol. 34, pp. 97–105, 2017.

[41] L. Lu, D.-T. Wang, Y. Shi et al., “Astragalus polysaccharide improves muscle atrophy from dexamethasone- and peroxide-induced injury in vitro,” *International Journal of Biological Macromolecules*, vol. 61, pp. 7–16, 2013.

[42] M.-H. Jung, J.-M. Yoo, Y.-J. Kang et al., “Idesolide, an isolate of idesia polycarpa, inhibits apoptosis through induction of...
intracellular heat shock protein 70 in C2C12 muscle cells," *Biological & Pharmaceutical Bulletin*, vol. 33, no. 6, pp. 1063–1066, 2010.

[43] T. Takeda, K. Tsuji, B. Li, M. Tadakawa, and N. Yaegashi, “Proliferative effect of Hachimijiogan, a Japanese herbal medicine, in C2C12 skeletal muscle cells,” *Clinical Interventions in Aging*, vol. 10, pp. 445–451, 2015.

[44] M.-H. Jung, M.-C. Song, K. Bae et al., “Sauchinone attenuates oxidative stress-induced skeletal muscle myoblast damage through the down-regulation of ceramide,” *Biological & Pharmaceutical Bulletin*, vol. 34, no. 4, pp. 575–579, 2011.

[45] D. Chen, J. Liu, L. Lu et al., “Emodin attenuates TNF-α-induced apoptosis and autophagy in mouse C2C12 myoblasts though the phosphorylation of Akt,” *International Immunopharmacology*, vol. 34, pp. 107–113, 2016.

[46] Y. Kang, C. Park, M. Han et al., “Ethanol Extract of Schisandra chinensis (Turcz.) Baill. Reduces AICAR-induced Muscle Atrophy in C2C12 Myotubes,” *Life Science Journal*, vol. 25, no. 3, pp. 293–298, 2015.

[47] Y. H. Choi, “Protective Effects of Isorhamnetin against Hydrogen Peroxide-Induced Apoptosis in C2C12 Murine Myoblasts,” *Journal of Korean Medicine for Obesity Research*, vol. 15, no. 2, pp. 93–103, 2015.

[48] P. Li, X. Li, X. Peng et al., “Ginsenoside Rgl prevents starvation-induced muscle protein degradation via regulation of AKT/mTOR/FoxO signaling in C2C12 myotubes,” *Experimental and Therapeutic Medicine*, vol. 14, no. 2, pp. 1241–1247, 2017.

[49] E. Morey-Holton and T. J. Wronski, “Animal models for simulating weightlessness,” *The Physiologist*, vol. 24, no. 6, pp. S-45–S-48, 1981.

[50] G.-L. Ye, K. V. Savelieva, P. Vogel et al., “Ethanolic extract of seabuckthorn (Hippophae rhamnoides L) prevents high-fat diet-induced obesity in mice through down-regulation of adipogenic and lipogenic gene expression,” *Nutrition Research*, vol. 32, no. 11, pp. 856–864, 2012.

[51] D. Attax, S. Ventadour, A. Codran, D. Béchet, D. Taillandier, and L. Combaret, “The ubiquitin-proteasome system and skeletal muscle wasting,” *Essays in Biochemistry*, vol. 41, pp. 173–186, 2005.

[52] W. S. Chen, P.-Z. Xu, K. Gottlob et al., “Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene,” *Genes & Development*, vol. 15, no. 17, pp. 2203–2208, 2001.

[53] D. J. Glass, “Molecular mechanisms modulating muscle mass,” *Trends in Molecular Medicine*, vol. 9, no. 8, pp. 344–350, 2003.

[54] J. O. Lipton and M. Sahin, “The Neurology of mTOR,” *Neuron*, vol. 84, no. 2, pp. 275–291, 2014.